PMID- 35774131
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific 
      TCR-T Cells for the Colorectal Cancer With Microsatellite Stability.
PG  - 895103
LID - 10.3389/fonc.2022.895103 [doi]
LID - 895103
AB  - Patients of colorectal cancer (CRC) with microsatellite stability (MSS) show poor 
      clinical response and little beneficial result from the immune-checkpoint 
      inhibitors, due to the 'cold' tumor microenvironment. Meanwhile, decitabine can 
      drive the 'cold' microenvironment towards 'hot' in multiple ways, such as 
      upregulating the tumor associated antigen (TAA) and human leukocyte antigen (HLA) 
      molecular. NY-ESO-1, one of the most important TAAs, can be observably induced in 
      tumors by low dose decitabine, and present itself as ideal targets for antigen 
      specific T cell receptor engineered T (TCR-T) cells. We innovatively used a 
      synergistic tactic, combining decitabine and NY-ESO-1 specific TCR-T cells, for 
      fighting the MSS CRC. Firstly, we confirmed the lysing effect of the NY-ESO-1 
      TCR-T cells on the NY-ESO-1(+) and HLA-A2(+) cells in vitro and in vivo. In A375 
      tumor-bearing mice, the results showed that NY-ESO-1 TCR-T cell therapy could 
      inhibit A375 tumor growth and prolonged the survival time. Furthermore, the 
      synergistic effect of decitabine and NY-ESO-1 TCR-T cells was shown to induce an 
      even higher percentage of tumor cells being lysed in vitro than other control 
      groups, and more potent tumor inhibition and longer survival time were observed 
      in vivo. The innovative synergistic therapeutic strategy of decitabine and TCR-T 
      cells for the CRC with MSS may be also effective in the treatment of other 
      epithelial malignancies. Decitabine may likewise be adopted in combination with 
      other cellular immunotherapies.
CI  - Copyright (c) 2022 Yu, Wang, He, Xu, Xu, Wan and Wu.
FAU - Yu, Ganjun
AU  - Yu G
AD  - Department of Immunology, College of Basic Medicine & National Key Laboratory of 
      Medical Immunology, Naval Medical University, Shanghai, China.
FAU - Wang, Wenying
AU  - Wang W
AD  - Department of Immunology, College of Basic Medicine & National Key Laboratory of 
      Medical Immunology, Naval Medical University, Shanghai, China.
FAU - He, Xiaobo
AU  - He X
AD  - Department of Immunology, College of Basic Medicine & National Key Laboratory of 
      Medical Immunology, Naval Medical University, Shanghai, China.
FAU - Xu, Jia
AU  - Xu J
AD  - Department of Immunology, College of Basic Medicine & National Key Laboratory of 
      Medical Immunology, Naval Medical University, Shanghai, China.
FAU - Xu, Rongrong
AU  - Xu R
AD  - Department of Immunology, College of Basic Medicine & National Key Laboratory of 
      Medical Immunology, Naval Medical University, Shanghai, China.
FAU - Wan, Tao
AU  - Wan T
AD  - Department of Immunology, College of Basic Medicine & National Key Laboratory of 
      Medical Immunology, Naval Medical University, Shanghai, China.
FAU - Wu, Yanfeng
AU  - Wu Y
AD  - Department of Immunology, College of Basic Medicine & National Key Laboratory of 
      Medical Immunology, Naval Medical University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220614
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9239344
OTO - NOTNLM
OT  - T cell receptor engineered T cell
OT  - colorectal cancer
OT  - decitabine
OT  - microsatellite stability
OT  - synergistic therapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/02 06:00
MHDA- 2022/07/02 06:01
PMCR- 2022/01/01
CRDT- 2022/07/01 02:28
PHST- 2022/03/13 00:00 [received]
PHST- 2022/05/17 00:00 [accepted]
PHST- 2022/07/01 02:28 [entrez]
PHST- 2022/07/02 06:00 [pubmed]
PHST- 2022/07/02 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.895103 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jun 14;12:895103. doi: 10.3389/fonc.2022.895103. eCollection 
      2022.